Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway
Yongsheng Jia(National Clinical Research), Brian J. Czerniecki(Moffitt Cancer Center), Shari Pilon‐Thomas(Moffitt Cancer Center), Doris Wiener(Moffitt Cancer Center), Krithika N. Kodumudi(Moffitt Cancer Center), Payal Grover(University of Pennsylvania), Amrita Basu(University of Calcutta), Hyo S. Han(Moffitt Cancer Center), José R. Conejo-García(Duke University), Gary K. Koski(Kent State University), Qianxing Mo(Memorial Sloan Kettering Cancer Center), Ganesan Ramamoorthi(Moffitt Cancer Center), Yongzi Chen(Tianjin Medical University Cancer Institute and Hospital), Hatem Soliman(Moffitt Cancer Center), Hongtao Zhang(Chinese Academy of Sciences), Zhongsheng Tong(Tianjin Medical University Cancer Institute and Hospital), Mark I. Greene(University of Pennsylvania), Ricardo Costa(Moffitt Cancer Center), Colin Snyder(Moffitt Cancer Center), Catherine Lee(Sanford Burnham Prebys Medical Discovery Institute)
Cited by 56
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
|Cell|2015|921
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649